“revolutionising healthcare through continuously improving diagnostic solutions”

Randox Laboratories Limited

• Privately owned diagnostic and instrument company

• UK and Ireland’s largest indigenous diagnostic company

• Established in 1982

• Employs 850 people

• 200 scientists and engineers

We supply quality products to:• Hospitals, clinical laboratories and veterinary and research

laboratories

• Over 130 countries

• An estimated 60,000 clients using Randox products.

In 2009:• 4 billion diagnostic tests manufactured by Randox.

Our facilities may have been basic but we developed

excellent diagnostic

products, many of which we still

manufacture today!

Princess Royal Visit 1987

Staff Levels..

0

100

200

300

400

500

600

700

800

900

NU

MB

ER

OF S

TA

FF

82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 992000200120022004200520062007200820092010

Current Product Range

• Biochip Array Technology (Including Molecular)

• Clinical Chemistry analysers and reagents

• Quality Control systems

• Life Sciences Department

• Randox Testing Services

• Randox Health Checks

We now have

60,000 customers worldwide

and have achieved significant market share

Miami-Dade CountyCalifornia, USA

“We are very happy with the huge advantages that the Evidence Investigator has brought to our death investigation abilities.”

Dr Lee Hearn

Planned Population Federation of Korea (PPFK)Seoul, South Korea

“I am very happy with the performance of the Imola as my QC results from Korea's national EQA scheme are always perfect on the RX Imola.”

Randox Offices and Distributors

Collaborations Network

Randox has an extensive network of international collaborations

~

We collaborate with 35 universities and hospitals in 7 different countries

~

Including Queen’s University Belfast and the University of Ulster

20th position out of the estimated 20th position out of the estimated 1,850 diagnostic companies worldwide1,850 diagnostic companies worldwide

4th in QC serum and calibrators4th in QC serum and calibrators

Number 1 in supply to Number 1 in supply to

international EQA schemesinternational EQA schemes

Randox manufactures 8% of all clinical Randox manufactures 8% of all clinical chemistry tests in the worldchemistry tests in the world

Randox provides the reagents for 11% of Randox provides the reagents for 11% of all HDL Cholesterol tests executed all HDL Cholesterol tests executed

world wideworld wide

Last year we manufactured our Last year we manufactured our

40 billionth test40 billionth test

is a world class manufacturer !is a world class manufacturer !

Innovation

Our mission statement:

“Revolutionising healthcare through continuously improving diagnostic

solutions”

PRODUCT PORTFOLIO

Innovation

Products are designed and developed with the customer and patient in mind

~

Our rigorous design and development process ensures that all products are fit for purpose

PRODUCT PORTFOLIO

Biochip Array Technology

Primary research High throughput

Huge versatility of technology

Expanding portfolio

Complimentary clinical chemistry

Excellent QC throughout

Clinical

Randox has spent $225million

developing Biochip Array Technology

Randox Sales Conference October 2008

. . with over 400 new tests in development – more than any other company in the world

Highly innovative…

Randox in Cardiology

Randox has developed tests to

save 20% of patients lives

Cutting edge technology and novel biomarkers to

accurately diagnose patients with suspected

heart attacks

Respiratory Pathogen Biochip

Human coronavirus 229E/NL63Human coronavirus 229E/NL63

Streptococcus pneumoniaeStreptococcus pneumoniae

Haemophilus influenzaeHaemophilus influenzae

Moraxella catarrhalisMoraxella catarrhalis Influenza AInfluenza A

Influenza BInfluenza B

Chlamydophila pneumoniaeChlamydophila pneumoniae

Legionella pneumophilaLegionella pneumophila

Human bocavirus 1/2/3Human bocavirus 1/2/3

Human enterovirus A/B/CHuman enterovirus A/B/C

Human rhinovirus A/BHuman rhinovirus A/B

Human adenovirus B/C/EHuman adenovirus B/C/E

Mycoplasma penumoniaeMycoplasma penumoniae

Human parainfluenzavirus 1Human parainfluenzavirus 1

Human Respiratory Syncytial virus AHuman Respiratory Syncytial virus A

Human metapneumovirusHuman metapneumovirus

Staphylococcus aureusStaphylococcus aureus

Human Respiratory Syncytial virus BHuman Respiratory Syncytial virus B




Human coronavirus OC43/HKU1Human coronavirus OC43/HKU1

Randox 10-plex STI Biochip

Mycoplasma genitalium (MG)Mycoplasma genitalium (MG)Neisseria gonorrhoea (NG)Neisseria gonorrhoea (NG)

Chlamydia trachomatis (CT)Chlamydia trachomatis (CT)

Trichomonas vaginalis (TV)Trichomonas vaginalis (TV)

Treponema pallidum (TP)Treponema pallidum (TP)

Herpes simplex 1 (HSV1)Herpes simplex 1 (HSV1) Herpes simplex 2 (HSV2)Herpes simplex 2 (HSV2)

Mycoplasma hominis (MH)Mycoplasma hominis (MH)

Haemophilus ducreyi (HD)Haemophilus ducreyi (HD)

Ureaplasma urealyticum (UU)Ureaplasma urealyticum (UU)

10 pathogens detected in one PCR reaction!

10 pathogens detected in one PCR reaction!

9 patient samples hybridized in one carrier

Up to 54 samples run simultaneously

9 patient samples hybridized in one carrier

Up to 54 samples run simultaneously

Bladder Cancer

Development of diagnostic

algorithm to remove the

need for cystoscopy

Breast Cancer RNA/cDNA array

Low density chip-based cDNA

arrays, using a molecular

signature panel that can

divide breast tumours into

clinically relevant sub-types

• One in nine women will be affected by breast cancer• Complex disease involving a number of sub groups • Sub-groups have treatment & prognostic significance• Current IHC methodology is not standardised• Interpretation of IHC can be problematic• IHC relies on small number of targets for diagnosis

Aim: to accurately subtype breast cancer and

predict outcome using a gene expression array

Metabolic SyndromeDefined as the Clustering of Cardiovascular Risk Factors

with 20-25% of adults affected

Metabolic Syndrome ArraysI II

Adiponectin C-Peptide

C-reactive Protein (CRP) Ferritin

Cystatin C Insulin

Interleukin-1 alpha (IL-1α)

Interleukin-6 (IL-6)

Leptin

Plasminogen Activator Inhibitor-1 (PAI-1)

Resistin

Tumour Necrosis Factor-alpha (TNFα)

Co-morbidities of Metabolic Syndrome

• Cardiomyopathy• Coronary Heart Disease• Atherogenic Dyslipidemia• Peripheral and Cerebrovascular Disease• Calcific Aortic Valvular Disease• Type 2 Diabetes• Polycystic Ovary Syndrome (PCOS)• Non-Alcoholic Fatty Liver Disease (NFALD)• Cognitive Impairment• Cancer• Chronic Kidney Disease• Mental Health Conditions

Applicability of other arrays to metabolic conditions

– Adhesion molecules array– Cardiac arrays– Cerebral arrays– Cytokine arrays– Endocrine array

Synergy with other biochip arrays available

Ovarian Cancer RNA/cDNA array

Low density chip-based

cDNA arrays, using a

molecular signature panel

that can predict responders

and non-responders to

chemotherapy (Taxol and

Platinum-based)

Ovarian Cancer RNA/cDNA array

•Low density chip-based cDNA array

• Predicts responders and non-responders to platinum and taxol

chemotherapies (using Ovarian tumours as models)

• Provides a rapid (1 day) test prior to treatment

• Ensures the patient gets the best treatment at the right time

• Standardised and easy to use protocols

Disease prediction – Cardiac disease risk• Cardiovascular disease (CVD) is a complex multifactorial and polygenic disorder

• Results from interaction between genetic makeup and environment

• Identification of SNPs in known CVD genes may therefore aid in the identification of individuals at risk

• Use with Framingham score to better gauge patient risk

• This will permit lifestyle changes or target therapy

• Includes the best 20-SNP combination for prediction of cardiac disease – derived from GWAS and meta analyses

Randox TxB Cardio® Assay

Randox Health Checks

Due to the slowness of uptake of new tests by the health service, we decided to

set up Randox Health Checks, our own clinic

Randox Health Checks

Conclusion

With the unravelling of the Human Genome Project – the potential for life changing inventions is immense

~

We, at Randox, have developed the world’s most revolutionary technology – in fact a disruptive technology in Laboratory

Medicine

~

We can help improve the lives of many people in this world

Belfast is as good a place to do this as anywhere in the world

~

We have a highly educated workforce open to the world

~

All we need is entrepreneurial leadership to overcome hurdles and problems put in our way

~

Remember that Belfast has been the source of many inventions and significant entrepreneurial endeavours

Henry George Ferguson

Ferguson designed and built a new plough which was coupled to the tractor in

three-point linkage, so that both formed a single unit. This 'Ferguson System',

building on the earlier two-point linkage patented in 1919, was patented in 1928. Together with many other inventions, it

was to revolutionise farming.

John Dunlop

Dunlop’s great invention, of the inner tube for cycle tyres, came about more or less

by chance. In 1888 his small son was prescribed cycling as cure for a heavy cold; Dunlop hit on the idea of making the boy's tricycle more comfortable by

fitting it with inflated tubes, made of canvas and bonded together with liquid rubber. He patented this idea, using the word 'pneumatic' for the first time, in the

same year.

Invention is in our genes!

Thank you for listening…

“revolutionising healthcare through continuously improving diagnostic solutions”

“revolutionising healthcare through continuously improving diagnostic solutions”

Documents

Transcript of “revolutionising healthcare through continuously improving diagnostic solutions”